[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"henoch-schonlein-purpura\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:henoch-schonlein-purpura":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100283245","vcrc-tissue-repository-100283245",false,"NCT02967068","VCRC Tissue Repository","VCRC Tissue Biorepository Collection Protocol","Inclusion Criteria:\n\n* A participant will be deemed eligible for this study if the participant is\u002Fwas enrolled in another one of the VCRC observational\u002Flongitudinal protocols (5502, 5503, 5504, 5505, 5506, 5507, 5563) and\u002For one of the VCRC interventional studies (5522, 5523, 5526, 5527, or 5562).\n\nExclusion Criteria:\n\n* Inability to give informed consent (or their guardians in the case of children) and to sign the consent form.\n* Unwilling to allow the use of their tissue for research.","ALL",{"count":18,"type":19},1000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies. Analysis of these tissue specimens and linked clinical data collected through VCRC studies may lead to the identification and development of a series of translational research projects. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.",[23,24,25,26,27,28,29,30,31,32,33],"Aortitis","Cutaneous Vasculitis","Eosinophilic Granulomatosis With Polyangiitis","Giant Cell Arteritis","Granulomatosis With Polyangiitis (Wegener's)","Henoch-Schonlein Purpura","IgA Vasculitis","Microscopic Polyangiitis","Polyarteritis Nodosa","Takayasu Arteritis","Churg-Strauss Syndrome",[35,36,37,38,39,40,41,42],"CSS","EGPA","GCA","GPA","MPA","PAN","TAK","HSP","RECRUITING","2026-01-21",{"date":46,"type":47},"2026-01-22","ACTUAL",{"date":49,"type":47},"2016-11",{"date":51,"type":19},"2028-12",{"name":53,"class":54},"University of Pennsylvania","OTHER",8,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":73,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100511318","leflunomide-for-henoch-schonlein-purpura-100511318","NCT05937880","Leflunomide for Henoch-Schonlein Purpura","Leflunomide for Refractory Skin Henoch-Schonlein Purpura in Children","Lef for HSP","Inclusion Criteria:\n\n1. Age ranges from 1 to 18 years old;\n2. Patients meet the HSP diagnostic criteria;\n3. Refractory skin type HSP: Rashes are dense and large in area, often treated with antibiotics, antihistamines, calcium supplements, and glucocorticoids (2 mg\u002Fkg\u002Fd) for 5 days. The rash does not subside or fresh rash still appears, and frequently repeated more than 3 times during hospitalization.\n4. Parents or guardians agree to treatment and sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Individuals who are allergic to leflunomide;\n2. Concomitant severe underlying diseases (such as systemic malignancy, heart failure, liver and kidney failure, immune deficiency, severe infectious diseases, organ transplant surgery, or other current indications for emergency surgery);\n3. Patients with other digestive system diseases;\n4. Those who have previously used flumiphene in clinical trials;\n5. Excluding purpura caused by drugs, infectious factors, and other autoimmune diseases.\n6. Other situations where the researcher deems it inappropriate to participate in the study.","1 Year","18 Years",{"count":67,"type":19},36,"INTERVENTIONAL",[70],"NA","This study conducted a prospective, multicenter, one-arm clinical trial on the combination of leflunomide and steroid therapy for refractory skin Henoch-Schonlein Purpura in children on the basis of ethical principles. A one-year follow-up was conducted to evaluate the changes in the main indicators (frequency of rash recurrence) and secondary indicators (proportion of kidney damage, proportion of joint involvement, T lymphocyte subpopulations, and inflammatory factors) before and after treatment, Exploring the safety and effectiveness of leflunomide in the treatment of refractory skin type HSP in children, it is expected that leflunomide combined with conventional treatment can improve the remission rate of HSP children's skin purpura and reduce HSP recurrence. The research results are expected to bring new treatment methods and strategies for this group of patients.",[28],[74,28,75,76],"Leflunomide","Children","Efficacy","2023-07-01",{"date":79,"type":47},"2023-07-10",{"date":81,"type":47},"2023-01-01",{"date":83,"type":19},"2027-06-30",{"name":85,"class":54},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",1]